GO
| HSI1 | 25,042.71 | +291.93 | 202.73B |
| HSCEI1 | 8,339.63 | +114.23 | 56.78B |
| Back Zoom + Zoom - Block Traded | |
|
2026-09-21 13:23:35 Nomura issued a research report stating that 10 mainland regulatory authorities, including the Ministry of Industry and Information Technology, the National Development and Reform Commission, the National Medical Products Administration and the National Healthcare Security Administration, released the pharmaceutical industry's 15th Five-Year Plan (2026-2030) before market open on September 18. The plan reiterated the pharmaceutical industry's new positioning as an emerging pillar industry, while highlighting innovation and globalization, laying a solid foundation for industry development. The broker expected the plan to benefit innovative drugmakers and CRDMO companies. The broker said the plan proposed multiple quantitative targets, including average R&D expenditure by listed pharmaceutical companies accounting for more than 10% of sales (currently estimated at about 8%), first-in-class (FIC) drugs accounting for more than 25% of global market share (currently likely only in the low teens), innovative drug sales growth exceeding 20% (far faster than the overall industry growth of about 8% during the 14th Five-Year Plan period, with no overall industry figure mentioned this time), and more than five drugs with global sales exceeding USD1 billion (currently about two to three). Priority areas include siRNA/ASO, PROTAC/molecular glues, PDC, radioligand conjugates, bispecific/multispecific antibodies, ADC/RDC/AOC, CAR-T (including in vivo and universal types), iPSC, AAV, LNP, mRNA vaccines, as well as medical devices such as bioresorbable scaffolds, single-cell sequencing, AI pathology, surgical robots, closed-loop insulin pumps and brain-computer interface exoskeletons. Other areas include AI molecular design and DNA digital storage. The broker believed that compared with the 14th Five-Year Plan, innovation and globalization have been placed at the core, reflecting the industry's rapid development and improving global competitiveness in recent years. Once more stakeholders take action and more detailed policies are introduced, INNOVENT BIO (01801.HK), SKB BIO (06990.HK), WUXI APPTEC (02359.HK) and WUXI XDC (02268.HK) are expected to benefit. The broker maintained Buy ratings on the above stocks. (ad/da)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |